{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:33:44Z","timestamp":1791473624216,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.aohep.2022.100769","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T21:56:16Z","timestamp":1665179776000},"page":"100769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study"],"prefix":"10.1016","volume":"28","author":[{"given":"Samantha Thifani Alrutz","family":"Barcelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Souza","family":"Silva-Sperb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Abadie","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisse","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Concheski","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Truccolo","family":"Michalczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Uribe-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Thadeu Schmidt","family":"Cerski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themis Reverbel","family":"da Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-3199","authenticated-orcid":false,"given":"Valesca","family":"Dall'Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio Reis","family":"\u00c1lvares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2022.100769_bib0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2022.100769_bib0002","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4291\/wjgp.v8.i2.51","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk","volume":"8","author":"Patil","year":"2017","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.aohep.2022.100769_bib0005","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2022.100769_bib0006","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.gastrohep.2017.12.003","article-title":"Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline","volume":"41","author":"Aller","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100769_bib0007","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2022.100769_bib0008","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","article-title":"Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?","volume":"33","author":"Bhatia","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.aohep.2022.100769_bib0009","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/gutjnl-2018-318146","article-title":"miRNAs and NAFLD: from pathophysiology to therapy","volume":"68","author":"Gjorgjieva","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2022.100769_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11906-020-01080-y","article-title":"Efficacy of probiotics in patients of cardiovascular disease risk: a systematic review and meta-analysis","volume":"22","author":"Dixon","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.aohep.2022.100769_bib0011","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.3390\/nu12092762","article-title":"New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress","volume":"12","author":"Ferro","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.aohep.2022.100769_bib0012","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2012.06.005","article-title":"Non-alcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians","volume":"223","author":"Thakur","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.aohep.2022.100769_bib0013","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/01.CIR.0000053731.05365.5A","article-title":"Coming of age of C-reactive protein: using inflammation markers in cardiology","volume":"107","author":"Yeh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2022.100769_bib0014","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1152\/ajpendo.00604.2005","article-title":"Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes","volume":"291","author":"Lautam\u00e4ki","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.aohep.2022.100769_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0029-1222606","article-title":"Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome","volume":"35","author":"Targher","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.aohep.2022.100769_bib0016","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.4254\/wjh.v13.i12.2052","article-title":"Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis","volume":"13","author":"Longo","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.aohep.2022.100769_bib0017","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/jcm4121953","article-title":"MicroRNAs in nonalcoholic fatty liver disease","volume":"4","author":"Baffy","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.aohep.2022.100769_bib0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2022.100769_bib0019","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2022.100769_bib0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100769_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Tang","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.aohep.2022.100769_bib0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","article-title":"Elafibranor: a potential drug for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Westerouen Van Meeteren","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.aohep.2022.100769_bib0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100769_bib0024","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2022.100769_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/s0004-2803.201900000-36","article-title":"N-acetylcysteine and\/or ursodeoxycholic acid associated with metformin in non-alcoholic steatohepatitis: an open-label multicenter randomized controlled trial","volume":"56","author":"Oliveira","year":"2019","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.aohep.2022.100769_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.aohep.2022.100769_bib0027","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MEG.0000000000001371","article-title":"The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with non-alcoholic fatty liver disease - a systematic review and meta-analysis","volume":"31","author":"Khan","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100769_bib0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00125-020-05295-1","article-title":"The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis","volume":"64","author":"Bock","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.aohep.2022.100769_bib0029","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0030","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"CRN) NCRN. Non-alcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0031","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","author":"Williams","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.aohep.2022.100769_bib0032","first-page":"105","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"70","author":"Catapano","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.aohep.2022.100769_bib0033","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.aohep.2022.100769_bib0034","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2143\/AC.61.6.2017959","article-title":"Cardiovascular risk factors in first-degree relatives of patients with premature coronary artery disease","volume":"61","author":"Saghafi","year":"2006","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.aohep.2022.100769_bib0035","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2022.100769_bib0036","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13098-018-0347-0","article-title":"Optimal cut-off points for waist circumference in the definition of metabolic syndrome in Brazilian adults: baseline analyses of the Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"10","author":"Cardinal","year":"2018","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.aohep.2022.100769_bib0037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1479-5868-8-115","article-title":"Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review","volume":"8","author":"Lee","year":"2011","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.aohep.2022.100769_bib0038","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0039","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2022.100769_bib0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2022.100769_bib0041","first-page":"1","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur J Prev Cardiol 2016"},{"key":"10.1016\/j.aohep.2022.100769_bib0042","first-page":"78","article-title":"Atherogenic indices in stroke patients: a retrospective study","volume":"16","author":"Sujatha","year":"2017","journal-title":"Iran J Neurol"},{"key":"10.1016\/j.aohep.2022.100769_bib0043","first-page":"359","article-title":"Atherogenic index of plasma, castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk","volume":"3","author":"Bhardwaj","year":"2013","journal-title":"Int J Pharm Biol Sci"},{"key":"10.1016\/j.aohep.2022.100769_bib0044","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/1596-3519.194280","article-title":"Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in Nigeria","volume":"15","author":"Olamoyegun","year":"2016","journal-title":"Ann Afr Med"},{"key":"10.1016\/j.aohep.2022.100769_bib0045","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12072-021-10157-y","article-title":"Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?","volume":"15","author":"Guerreiro","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2022.100769_bib0046","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.aohep.2022.100769_bib0047","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.aohep.2022.100769_bib0048","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5005\/jp-journals-10018-1233","article-title":"Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis","volume":"7","author":"Lavekar","year":"2017","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.aohep.2022.100769_bib0049","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP \u00ae BCMC \u00ae strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.aohep.2022.100769_bib0050","doi-asserted-by":"crossref","first-page":"8805","DOI":"10.3390\/ijms23158805","article-title":"The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"23","author":"Carpi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.aohep.2022.100769_bib0051","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/fmb.15.13","article-title":"Systematic review on intervention with prebiotics\/probiotics in patients with obesity-related non-alcoholic fatty liver disease","volume":"10","author":"Tarantino","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.aohep.2022.100769_bib0052","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.aohep.2022.100769_bib0053","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/07853890.2015.1071872","article-title":"Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Sun","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.aohep.2022.100769_bib0054","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4158\/EP151157.RA","article-title":"Prebiotics, probiotics, and synbiotics in management of obesity and prediabetes: review of randomized controlled trials","volume":"22","author":"Microbiota","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.aohep.2022.100769_bib0055","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Non-alcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0056","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s12072-013-9480-x","article-title":"Epidemiology and risk factors of non-alcoholic fatty liver disease (NAFLD)","volume":"7","author":"Duseja","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2022.100769_bib0057","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0058","first-page":"1","article-title":"Racial density and the socioeconomic, demographic and health context in Brazilian cities in 2000 and 2010","volume":"22","author":"Oliveira","year":"2019","journal-title":"Rev Bras Epidemiol"},{"key":"10.1016\/j.aohep.2022.100769_bib0059","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2022.100769_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.aohep.2022.100769_bib0061","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40292-020-00389-8","article-title":"Evaluation of cardiovascular risk in patient with primary non-alcoholic fatty liver disease","volume":"27","author":"Pisetta","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.aohep.2022.100769_bib0062","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/CIRCULATIONAHA.114.009273","article-title":"Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study","volume":"130","author":"Xanthakis","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2022.100769_bib0063","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","article-title":"Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study","volume":"140","author":"Tofler","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.aohep.2022.100769_bib0064","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100769_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0153497","article-title":"Association of Circulating Serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease","volume":"11","author":"Salvoza","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2022.100769_bib0066","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1476-511X-11-55","article-title":"Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease","volume":"11","author":"Gao","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.aohep.2022.100769_bib0067","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of non-alcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:45:58Z","timestamp":1761648358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268122001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1665268122001119"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100769","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100769"}}